Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
BicycleTx Limited
ImmunityBio, Inc.
University of British Columbia
Ottawa Hospital Research Institute
CG Oncology, Inc.
University of Washington
University Hospital Birmingham NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Nippon Kayaku Co., Ltd.
Bristol-Myers Squibb
Endo Pharmaceuticals
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
National University Hospital, Singapore